News
Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...
8h
WISH-TV on MSNFDA-approved semaglutide aids weight loss and health conditions
Learn about the use of GLP-1 agonists for weight loss and health improvement by celebrities like Oprah and Serena Williams.
“Semaglutide is very effective for weight loss,” says Dr. Saunders. In fact, a 2021 phase 3 clinical trial found that 2.4 ...
Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
7d
MedPage Today on MSNSemaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Novo Nordisk A/S (NYSE: NVO) is one of the Most Undervalued International Stocks According to Analysts. On August 19, TD ...
There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...
Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...
Oral semaglutide, known as the oral version of Ozempic, is revolutionising chronic disease management beyond just blood sugar ...
Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results